Pembrolizumab Plus Chemotherapy Enters Frontline Treatment Landscape of Advanced Esophageal Cancer

in the phase 3 KEYNOTE-590 clinical trial, frontline pembrolizumab plus chemotherapy demonstrated a significant improvement in overall survival, progression-free survival, and objective response rates versus chemotherapy only in patients with locally advanced unresectable or metastatic esophageal cancer, result presented during the 2020 EsMO Virtual Congress show.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *